Mar 12, 2024 / 07:35PM GMT
Charles Pitman Barclays-Analyst
Hey, we'll make a start. So thank you, everyone, for joining us this afternoon. My name is Charles Pitman. I work on the European pharma team covering Mid-Cap pharma and life sciences stocks. And I'm very pleased to be joined today by Karl Gubitz, CFO of argenx.
Karl Gubitz - argenx SE - CFO
Thank you, Charles. It's really great to be. Thank you for the conference.
Questions and Answers:
Charles Pitman Barclays-AnalystAbsolutely. And just starting with maybe a kind of overarching perspective on argenx. I know that you've originally had time at Pfizer, kind of large pharma background maybe if you could just start with talking about, you know, how the argenx approach differs, how the management team really worked together to ensure efficiency and what they're doing. And given you have so many things to be spend your money on balance that line between cost control and investment?
Karl Gubitz - argenx SE - CFO
Yes, Thank
Trustpilot
